A potential panel of two-long non-coding RNA signature to predict recurrence of patients with laryngeal cancer

Abstract

Accumulating evidence has shown that aberrant lncRNA expression plays an oncogenic or tumor-suppressive role in the tumorigenesis of laryngeal cancer. However, the prognostic roles of lncRNAs in laryngeal cancer recurrence are still poorly understood. In this study, we obtained lncRNA expression profiles of 109 patients with laryngeal cancer by mining previously published gene expression microarray data from the Gene Expression Omnibus (GEO) and identified two lncRNAs associated with laryngeal cancer recurrence in the training dataset by using Cox regression analysis. Then these two lncRNAs were combined to a two-lncRNA signature for identifying patients at high-risk of disease recurrence. By applying this two-lncRNA signature to the testing dataset, a clear separation was observed in the survival curves between patients with low- or high-risk scores, indicating good reproducibility of this two-lncRNA signature in predicting disease-free survival of laryngeal cancer. Further analysis revealed that the prognostic value of the two-lncRNA signature was independent of other clinical features, including age, stage and grade. Subsequent gene set enrichment analysis suggested that the two-lncRNA signature was more likely to involve with GPCRs downstream signaling pathway, potassium channel pathway and aurora-A pathway. Our study demonstrated that the two-lncRNA signature may be a novel potential biomarker for prognosis of laryngeal cancer and may provide novel insights into the molecular mechanism of laryngeal cancer.

Signature microRNAs and long noncoding RNAs in laryngeal cancer recurrence identified using a competing endogenous RNA network

“…NF-κB-interacting lncRNA was identified to inhibit tumor cell viability and to promote apoptosis (17). A previous study analyzed an lncRNA expression dataset from the Gene Expression Omnibus (GEO) database, and identified that two lncRNAs, RP11-169K16.4 and RP11-107E5.3, were associated with the prediction of recurrence of laryngeal cancer (18).…”

Long non-coding RNA TRPM2-AS as a potential biomarker for hepatocellular carcinoma

“…Using high-throughput technologies, thousands of lncRNAs have recently been identified, and a large number of studies have demonstrated that dysregulated lncRNAs are closely related to human cancers [7], such as HCC [8], lung cancer [9], breast cancer [10], and colorectal cancer [7]. The expression levels of certain lncRNAs are associated with the recurrence [11], metastasis [12], and prognosis of cancers. Therefore, the identification of cancer-associated lncRNAs will lead to a better understanding of the molecular biology of tumors and aid in developing novel therapeutic targets.…”

Prognostic Significance of Oxidation Pathway Mutations in Recurrent Laryngeal Squamous Cell Carcinoma

“…Recurrent LSCC in the setting of previous radiation or chemoradiation represents an aggressive disease with significant treatment related morbidity [ 8 , 24 , 25 , 26 , 27 ]. While there has been significant focus on understanding the genomic landscape of primary laryngeal squamous cell carcinoma [ 28 , 29 , 30 , 31 , 32 , 33 , 34 ], few studies have explored molecular signatures of recurrent disease [ 13 , 15 , 16 , 17 ]. Here we present results from a recurrent laryngeal carcinoma cohort with targeted sequencing and transcriptome data that identified multiple pathways predictive of survival independent of clinical variables.…”

“…A study by Lee et al further identified alterations in p53 expression between previously untreated LSCC and matched recurrent tumors after radiation [14]. While these data offer some insight into the nature of recurrent laryngeal disease, clinically actionable implications remain aspirational [15][16][17].…”